Clinical Trials › NCT05758831
RecruitingPhase 3
RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
Sponsored by Rennes University Hospital
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 386
Target enrollment
Jun 2023
Start date
May 2030
Expected completion
Interventions / Treatments
Perfusion of treatment RituximabPerfusion of treatment Ocrelizumab
Conditions studied
Multiple SclerosisRelapsing-remitting Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 3 trials
Browse all Phase 3 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.